Glucagonoma Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 18, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Glucagonoma. It connects disease background, epidemiology, a target-mechanism anchor, clinical competition, transaction activity, unmet need and market attractiveness for portfolio and business-development decisions.

Executive assessment

Glucagonoma receives a directional strategic score of 69/100. The synthesis combines unmet need (83/100), competitive intensity (61/100, where a higher value means more competition) and market attractiveness (74/100). It is an evidence-organizing framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

An almost always malignant GLUCAGON-secreting tumor derived from the PANCREATIC ALPHA CELLS. It is characterized by a distinctive migratory ERYTHEMA; WEIGHT LOSS; STOMATITIS; GLOSSITIS; DIABETES MELLITUS; hypoaminoacidemia; and normochromic normocytic ANEMIA.

The reproducible entity is Patsnap disease ID 3a4163a23a854547ad1a70e3e7cb95b6 with MeSH identifier D005935. Entity-level identifiers matter because rare disorders often carry historical names, gene-defined subtypes and overlapping clinical labels. Strategy teams should lock the intended label and synonym set before comparing epidemiology, trials and deals.

A useful target product profile must specify the treatable phenotype, age and severity range, diagnostic confirmation, prior-therapy requirements, treatment setting, acceptable safety profile and endpoint. In Glucagonoma, an overly broad label can inflate the theoretical market while diluting biological signal and making recruitment less predictable.

The care pathway should be mapped from symptom recognition through specialist referral, molecular or biochemical confirmation, treatment initiation and longitudinal monitoring. Diagnostic delay, fragmented referral and limited centers may be as important commercially as drug efficacy. These barriers should appear explicitly in launch and evidence-generation plans.

Epidemiology and disease burden

Epidemiology signal 1: Burden, trends, and predictions of liver cancer in China, Japan, and South Korea: analysis based on the Global Burden of Disease Study 2021 Burden, trends, and predictions of liver cancer in China, Japan, and South Korea: analysis based on the Global Burden of Disease Study 2021

1. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomata- ram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 coun- tries. CA Cancer J Clin. 2024;74(3):229–263 2. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008;14(27):4300–4308 3. Choi S, Kim BK, Yon DK, Lee SW, Lee HG, Chang HH, et al. Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differ- ences from 1990–2019: a DALY-based analysis of the Global Bur- den of Disease 2019 study. Clin Mol Hepatol. 2023;29(2):433–452 4. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepato- cellular carcinoma. Hepatology (Baltimore, MD). 2021;73(Suppl 1):4–13 5. Sohn W, Lee HW, Lee S, Lim JH, Lee MW, Park CH, et al. Obe- sity and the risk of primary liver cancer: a systematic review and meta-analysis. Clin Mol Hepatol. 2021;27(1):157–174 6. Ho NT, Abe SK, Rahman MS, Islam R, Saito E, Gupta PC, et al. Diabetes is associated with increased liver cancer incidence and mortality in adults: a report from Asia Cohort Consortium. Int J Cancer. 2024;155(5):854–870 7. Ko KP, Shin A, Cho S, Park SK, Yoo KY. Environmental con- tributions to gastrointestinal and liver cancer in the Asia-Pacific region. J Gastroenterol Hepatol. 2018;33(1):111–120 8. Sarin SK, Kumar M, Eslam M, George J, Al Mahtab M, Akbar SMF, et al. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepa

Review the underlying epidemiology source

Epidemiology signal 2: 2020年中国与全球结直肠癌流行概况分析 Ｐｒｅｖａｌｅｎｃｅｏｆｃｏｌｏｒｅｃｔａｌｃａｎｃｅｒｉｎ２０２０：ａｃｏｍｐａｒａｔｉｖｅａｎａｌｙｓｉｓｂｅｔｗｅｅｎＣｈｉｎａａｎｄｔｈｅｗｏｒｌｄ

【关键词】 结直肠肿瘤； ＧＬＯＢＯＣＡＮ２０２０； 流行； 疾病负担 基金项目：北京市医院管理局登峰人才计划（ＤＦＬ２０１８１１０３） ＤＯＩ：１０．３７６０／ｃｍａ．ｊ．ｃｎ１１２１５２⁃２０２２１００８⁃００６８２ Ｐｒｅｖａｌｅｎｃｅｏｆｃｏｌｏｒｅｃｔａｌｃａｎｃｅｒｉｎ２０２０：ａｃｏｍｐａｒａｔｉｖｅａｎａｌｙｓｉｓｂｅｔｗｅｅｎＣｈｉｎａａｎｄｔｈｅｗｏｒｌｄ ＹａｎＣｈａｏ，ＳｈａｎＦｅｉ，ＬｉＺｉｙｕ ＫｅｙＬａｂｏｒａｔｏｒｙｏｆＣａｒｃｉｎｏｇｅｎｅｓｉｓａｎｄＴｒａｎｓｌａｔｉｏｎａｌＲｅｓｅａｒｃｈ，ＭｉｎｉｓｔｒｙｏｆＥｄｕｃａｔｉｏｎ／Ｂｅｉｊｉｎｇ，Ｇａｓｔｒｏｉｎｔｅｓｔｉｎａｌ ＣａｎｃｅｒＣｅｎｔｅｒ，ＰｅｋｉｎｇＵｎｉｖｅｒｓｉｔｙＣａｎｃｅｒＨｏｓｐｉｔａｌ＆Ｉｎｓｔｉｔｕｔｅ，Ｂｅｉｊｉｎｇ１００１４２，Ｃｈｉｎａ Ｃｏｒｒｅｓｐｏｎｄｉｎｇａｕｔｈｏｒ：ＬｉＺｉｙｕ，Ｅｍａｉｌ：ｚｉｙｕ＿ｌｉ＠ｈｓｃ．ｐｋｕ．ｅｄｕ．ｃｎ

Review the underlying epidemiology source

Epidemiology signal 3: 中国及全球胰腺癌流行特征分析 Epidemiological characteristics of pancreatic cancer in China and worldwide

Epidemiological characteristics of pancreatic cancer in China and worldwide Wang Jun 1, Ding Lulu 1, Yan Yongfeng 1, Chen Yongsheng 1, Xu Yuanyou 1, Lu Lingling 1, Gong Haijian 2, Zhu Jian 1 1 Department of Etiology, Affiliated Qidong Hospital of Nantong University, Qidong Liver Cancer Institute, Qidong 226200, China; 2Department of Oncology, Qidong People's Hospital, Qidong 226200, China Corresponding authors: Gong Haijian, Email: 931785869@qq.com; Zhu Jian, Email: jsqdzj8888@sina.com 【Abstract】 Objective To analyze pancreatic cancer incidence and mortality data in China and worldwide and to provide data for pancreatic cancer prevention and control efforts. Methods Data of pancreatic cancer incidence and mortality rates, along with historical and predictive data, were obtained from the GLOBOCAN 2022 database. Epidemiological characteristics of pancreatic cancer was analyzed by region, sex, age and Human Development Index (HDI). Spearman's correlation coefficient test was used to assess the relationship between HDI and age-standardized incidence rate (ASIR) and age-standardized mortality rate (ASMR). Results In 2022, the global number of new cases and deaths of pancreatic cancer will be 511 thousand and 467 thousand, respectively, with an ASIR and ASMR of 4.7/10 5 and 4.2/10 5, respectively. North America and Europe had the highest pancreatic cancer incidence and mortality rates of 8.5/10 5 and 7.3/10 5, respectively. Global ASIR and ASMR in men were both 1.4 times higher than those in women. HDI levels were positively correlated with ASIR (r=0.79, P＜0.001) and ASMR (r=0.78

Review the underlying epidemiology source

Epidemiology should be converted into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence are not interchangeable; estimates from different age bands, case definitions or health systems should not be pooled without adjustment.

For Glucagonoma, the next population work should quantify diagnostic yield, severity distribution, referral-center concentration, treatment penetration and survival or progression. Sensitivity analyses should show how each assumption affects recruitment, peak penetration and budget impact. A transparent range is more useful than a single precise-looking estimate built from incompatible sources.

Unmet need and patient-value thesis

The unmet-need thesis must name the failure that a new intervention will change: irreversible progression, incomplete disease control, treatment-limiting toxicity, burdensome administration, weak durability, delayed diagnosis or lack of options for a biomarker-defined subgroup. High disease severity alone does not prove that a clinical program can demonstrate benefit.

A strong Glucagonoma strategy connects mechanism to a pre-specified responder population and an endpoint understood by regulators, clinicians, patients and payers. It also tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Patient-reported outcomes, functional measures and health-resource use may add value when standard biomarkers do not capture daily burden.

The recommended first development population is the narrowest segment that remains operationally recruitable and has the clearest biological rationale. Expansion should follow evidence of target engagement and response rather than precede it. This sequencing protects capital and improves the interpretability of early clinical results.

Target mechanism anchor: PTH1R

G protein-coupled receptor for parathyroid hormone (PTH) and for parathyroid hormone-related peptide (PTHLH) (PubMed:10913300, PubMed:18375760, PubMed:19674967, PubMed:27160269, PubMed:30975883, PubMed:35932760, PubMed:8397094). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (cAMP) (PubMed:30975883, PubMed:35932760). PTH1R is coupled to G(s) G alpha proteins and mediates activation of adenylate cyclase activity (PubMed:20172855, PubMed:30975883, PubMed:35932760). PTHLH dissociates from PTH1R more rapidly than PTH; as consequence, the cAMP response induced by PTHLH decays faster than the response induced by PTH (PubMed:35932760).

The mechanism anchor for this landscape is PTH1R. It is a pathway hypothesis, not an assertion that every patient is target-dependent. Translational diligence should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream pathway modulation and a therapeutic window in the intended population.

Critical experiments include orthogonal engagement assays, dose–response work in disease-relevant systems, biomarker qualification, evaluation of compensatory pathways and explicit on-target and off-target safety testing. Human evidence should receive more weight than model-only findings. Negative results in related mechanisms should be analyzed for exposure, population, endpoint and biological lessons.

A go decision requires a chain of evidence: target present in the relevant tissue; modulation achieved at tolerated exposure; pharmacodynamic change observed; and that change plausibly connected to clinical benefit. If any link is missing, the program should remain at a lower investment gate.

Clinical development and competition

The focused query returned 19 registered studies overall. Recent sampled records include:

• NCT07558681 — Perioperative Pharmacokinetic/Pharmacodynamic Target Attainment of Piperacillin During Major Hepatic and Pancreatic Surgery (PROPHTAZ); status Not yet recruiting; phase Not Applicable; sponsor Central Hospital Ltd.; enrollment 60.
• NCT03583528 — DOTATOC PET/CT for Imaging NET Patients; status Active, not recruiting; phase Not Applicable; sponsor British Columbia Cancer Agency; enrollment 800.
• NCT03147768 — Laser Tissue Welding - Distal Pancreatectomy Sealing Study (LTW); status Completed; phase Phase 1; sponsor Laser Tissue Welding, Inc., National Cancer Institute, CHI St. Luke’s Health; enrollment 11.

Trial count is not equivalent to the number of competing products. Observational studies, natural-history cohorts and multiple trials from one asset can distort the headline. Each record should be normalized by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy must compare against the likely standard of care at launch, not only today's treatment. Potential whitespace may come from earlier intervention, genotype selection, improved durability, reduced monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim should be visible in protocol design and prospectively defined analyses.

Recruitment risk deserves its own workstream in Glucagonoma. Site density, diagnostic testing, competing protocols, travel burden and screen-failure rates should inform country and center selection. Natural-history data can reduce uncertainty but should not substitute for a well-controlled efficacy strategy when endpoints are variable.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This negative signal can mean limited partnering momentum, a broader deal label or asset-level transactions not indexed to the exact indication. Target- and asset-based comparable searches should be added before valuation.

Headline deal value is rarely a clean comparable. Upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope must be separated. A defensible comparable set matches indication, target, modality, stage and territory, then explains every remaining difference.

Partner readiness depends on a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual-property position, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that can retire a material portion of risk.

For Glucagonoma, direct transaction scarcity can create whitespace, but it can also signal weak validation or a difficult commercial model. Broader pathway deals are useful only when their scientific and economic relevance is made explicit. Avoid treating unrelated rare-disease transactions as interchangeable simply because both populations are small.

Market attractiveness and access

Market attractiveness is shaped by diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, current alternatives, monitoring burden and geographic reimbursement. A rare population can still be attractive when identification is reliable, centers are concentrated and effect size is meaningful; a larger population can disappoint when diagnosis and access are fragmented.

The commercial model should include conservative, base and upside scenarios. Key variables are diagnosed prevalence, eligible share, launch timing, competing approvals, net price, persistence and achievable penetration. Each assumption should have a source, date and range. Scenario outputs should be updated when new epidemiology, trial or transaction evidence arrives.

Payer research should begin before pivotal design so comparator, endpoint and follow-up choices support reimbursement as well as approval. Evidence plans may need quality-of-life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The strongest value proposition ties clinical benefit to outcomes that matter across stakeholders.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate that PTH1R is relevant in the selected phenotype.
• Translation risk: connect engagement to a biomarker and clinically meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing capacity and screen-failure assumptions.
• Commercial risk: test access, pricing and adoption with clinicians and payers.
• Data risk: interpret zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are: confirm population and natural history; validate mechanism in human evidence; define a differentiated target product profile; establish early proof of mechanism; and scale only after clinical signal, operational feasibility and commercial logic converge. Every gate needs pre-agreed stop criteria.

Strategic recommendation

Glucagonoma merits continued, milestone-based evaluation. The opportunity is strongest if a biomarker or phenotype can identify patients with coherent biology, if PTH1R modulation is measurable, and if the proposed benefit is meaningful against future care. The current evidence supports further diligence rather than an unconditional investment decision.

The near-term business-development objective is to build a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard provides a common language for comparison, while the attached evidence and explicit gaps preserve analytical traceability.

Methodology and source note

This report was assembled on August 18, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update. Counts are directional search outputs, not clinical, regulatory or investment advice.

Ranking weights are 40% unmet need, 25% inverse competitive intensity and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Before a transaction or portfolio commitment, rerun searches with synonyms, disease roll-ups, gene or pathway names and asset filters.

Conclusion

The central question for Glucagonoma is whether a biologically grounded therapy can produce a material patient benefit in an identifiable population and remain differentiated through launch. The current evidence supplies a structured starting point; the gaps define the next diligence plan. Connected MCP searches make the thesis refreshable as disease knowledge, trials and transactions evolve.